Hans-Jorg Senn Livres

This totally revised and expanded reference provides comprehensive, single-source coverage of the multiple approaches caregivers take to relieve the emotional distress and physical discomfort of patients suffering from neoplasia. By supplying practical guidelines to diagnose and treat complications arising from antineoplastic therapy and elaborating on topics originally presented in the first edition, the Second Edition of Supportive Care in Cancer contains new chapters on complementary and alternative medical techniques for cancer support care and on cancer care in the home offers the latest thoughts regarding the importance of educating and counseling patients supplies an updated bibliography and nearly 1900 references-500 new to this edition-to assist with further study covers the most frequent and life-threatening problems-including infection and metabolic derangement-in greater detail addresses sexual adjustments made by patients to cancer and its therapy explores fungal, viral, and other uncommon infections gives a new emphasis on hospice and terminal care examines fatigue and the management of side effects through physical, psychological, and spiritual assistance considers dermatological complications and more!

Universite Libre de Bruxelles, Belgium. Reference for all who care for cancer patients. Defines supportive care as the totality of medical, nursing, psychosocial, and rehabilitation support from diagnosis to cure or death. 38 contributors, 13 U.S. Neoplasms - therapy.

Pharmacologic interventions to prevent the evolution of human cancers are still in its infancy, although a good number o- mostly controlled - clinical studies have been performed in the past two decades. However, regarding the partially stagnating therapeutic results of major epithelial cancer types such as breast-, lung-, colon- and ENT-cancer types, the problem of in terference with the evolution of disease at a preclinical level is an intriguing one, and the field seems to develop into one of the fastest growing domaines of modern oncology. This process is fa cilitated by the developments of molecular on co-genetics and the gowing existence of family cancer units, allowing to better identi fy and inform respective high risk groups, thus enabling re searchers and clinicians to more realistically target their chemo preventive efforts to the true populations at risk. On this changing background, the newly formed International Society of Cancer Chemoprevention (ISCaC) together with the Swiss Cancer League and the Interdisciplinary Oncology Center of St. Gallen/Switzerland organized an international Symposium in September 1997, inviting basic researchers, epidemiologists and clinical oncologists of related disciplines to discuss pertinent issues of experimental and clinical chemo- and bio-prevention in a scientific workshop.

This RRCR-conference volume represents the sixth installment in a 20-year journey of international conferences focused on the adjuvant therapy of primary breast cancer. Beginning in 1978, around 80 dedicated breast cancer surgeons and oncologists convened in a secluded Swiss mountain resort to share early data from pioneering trials on adjuvant systemic therapy. Their aim was to address the stagnation in prognosis for this prevalent disease among Western women. Held every 3-4 years, the St. Gallen International Conferences have expanded significantly, both in participant numbers and in their influence on therapeutic norms, with findings published in major oncology journals. The most recent conference, from February 25-28, 1998, attracted over 1800 attendees from more than 50 countries. The ongoing interest in adjuvant therapy for early breast cancer raises questions about the developments over the past three years that warrant such a large gathering of leading experts. Enhancing care and formulating effective recommendations for patients with early breast cancer or those at high risk remain crucial public health objectives.

This work presents aspects of adjuvant therapy of breast cancer and discusses topics such as: epidemiology and genetics of breast cancer; biology of breast cancer; prognosis of response and tumour markers; and screening for breast cancer and treatment of early lesions.